Patients completed a @-month loading phase with monthly intravitreal injections of @ mg ranibizumab , followed by a @-month maintenance phase during which investigators documented VA , additional injections , metamorphopsias , routine ophthalmological examinations and adverse events at monthly follow-up visits .